Cediranib failed to improve progression free survival as a monotherapy and in conjunction with Lomustine.57 Similarly, Vandetanib a dual inhibitor of VEGFR-2 and EGFR that was tested in a phase II trial for recurrent GBM also had little efficacy in patients with GBM.58 This evidence concerns the gene EGFR and glioblastoma.